Dendrimers and Polymer Drug Conjugates Market, 2016 - 2026

  • ID: 3771276
  • Report
  • Region: Global
  • 183 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • 3S Bio
  • Baxalta
  • Delta-Fly Pharma
  • Merck
  • PolyPid
  • Sonoran Biosciences
  • MORE
The “Dendrimers and Polymer Drug Conjugates Market, 2016-2026” report delivers a comprehensive study on the emergence of nanocarriers as a significant tool for drug delivery, therapeutics and diagnostics. For the purpose of this report, we have primarily focused on the following two types of nanocarriers.

- Dendrimers
- Polymer drug conjugates

Dendrimers, the nanoscale hyper-branched structures, are evolving in the healthcare sector to enhance the properties of existing therapeutic compounds as well as for introduction of novel therapeutic/diagnostic products. VivaGel® by Starpharma is a commercially available therapeutic product; in addition, transfection kits and diagnostic assays are also available. However, from a commercial perspective, market of dendrimers is still in its infancy within the biomedical sector. The domain is gradually gaining traction with several technologies and approaches being designed for improving drug release properties. In addition to drug delivery, which is the key application area, some other potential applications of dendrimers being actively pursued in research include disease diagnosis, targeted therapy, MRI imaging, tissue regeneration, cell repair and vaccine development.

A parallel field of polymer therapeutics includes introduction of polymers with conventional drugs; these are more commonly known as polymer drug conjugates. Conjugation of drugs with polymers has demonstrated a marked improvement in their efficacy and release profiles. For the purpose of our study, we have included the molecules in the clinical/preclinical development (defined as per the Ringsdorf Model). Numerous polymer drug conjugates have already been commercialized for a wide range of therapeutic areas; our study provides an analysis of key disease areas being targeted by the developers of polymer drug conjugates. Several well-known anti-cancer drugs such as docetaxel, paclitaxel and doxorubicin have been conjugated with polymers such as PEG, HPMA and PLA to enhance their water solubility, half-life, efficacy and body clearance.

The report assesses key drivers that have governed the evolution of polymer drug conjugates over the past several years and determines the market in a long term (2016-2026). The research, analysis and insights presented in this report include potential sales of the drugs in phase III and phase II of development. To add robustness to our forecast model, we have provided three market scenarios. The conservative, base and optimistic scenarios represent three different tracks of market evolution. In addition, we have provided a detailed discussion on the future trends and the key opportunity areas for dendrimers that are likely to shape the market in the coming years.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

- Nearly 40 polymer drug conjugates are currently in clinical and preclinical stages of development; molecules in phase III and II account for nearly 19% of the pipeline while 26% is captured by molecules in phase I/II and I.

- There are several types of dendrimers being used for both commercial and research purposes in the pharmaceutical domain; the dendrimers most widely used for industry applications include PAMAM, PLL, Priostar®, Astramol®. However, with over 4000 papers published between 2006 and 2016 (as reported in PubMed), dendrimers are being extensively explored by researchers in the non-industry / academic institutes.

- With one commercialized therapeutic product (VivaGel®) and several other marketed dendrimer-based products (SuperFect®, Stratus® CS, PrioFect™, Alert Ticket™), Starpharma has emerged as a forerunner in the dendrimer market.

- Amongst the different biomedical applications that dendrimers and polymer drug conjugates serve, drug delivery holds a large opportunity. Several big pharma players as AstraZeneca, Eli Lilly, GSK’s Stiefel have collaborated with dendrimer technology developers (such as DEP® Technology by Starpharma) to improve the therapeutic efficacy and drug delivery properties of their existing products. Additionally, polymer drug conjugates have expanded their focus to a broad range of diseases exploring different routes of administrations for better drug delivery.

- The polymer drug conjugates market momentum will be driven by the success of current batch of late stage clinical molecules; these primarily include NKTR-181 (by Nektar Therapeutics), NKTR-102 (by Nektar Therapeutics), CRLX101 (by Cerulean Pharma) and Opaxio™ (by CTI BioPharma).

- Specific molecules such as NKTR-181 and NKTR-102 are anticipated to achieve a block buster status in the near future. With eight molecules (two mentioned above and six others in lower stages of development) in development, Nektar Therapeutics is expected to play an important role in the market’s evolution.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

Chapter Outlines

Chapter 2 - provides an executive summary of the report. It offers a high level view on the present scenario of dendrimers and polymer drug conjugates and where they are headed in the mid to long term.

Chapter 3 - provides a general introduction to nanotechnology with a detailed discussion on its applications in the biopharmaceutical industry. This chapter discusses the various types of nanocarriers that have revolutionized drug delivery and other biomedical applications.

Chapter 4 - includes information on nearly 40 polymer drug conjugates that are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of polymers, type of drugs, most commonly targeted indications and the phase of development. In addition, we have provided a list of the different classes of dendrimers highlighting their developer, core molecules and surface groups.

Chapter 5 - provides an in-depth introduction to dendrimers. In this chapter, we have captured the most popular dendrimers used for development of diagnostics, therapeutics and other biomedical products; these are accompanied with detailed information on their structure, research applications and detailed product profiles of the commercialized products.

Chapter 6 - comprises of a comprehensive discussion on the advantages, applications and target disease areas of polymer drug conjugates. In addition, the chapter gives detailed profiles of phase III and phase II molecules including information of their developer, clinical trials and primary/secondary endpoints.

Chapter 7 - offers a comprehensive view on the market forecast of polymer drug conjugates measuring the opportunity in the next ten years. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market. In addition, we have presented a qualitative analysis of the opportunity areas of dendrimers highlighting their future potential.

Chapter 8 - summarizes the overall report. In this chapter, we have provided a recap of the key take aways and our overall opinion on where the market is headed in the mid-long term.

Chapter 9 - is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 10 - is an appendix, which provides a list of companies and organizations mentioned in the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3S Bio
  • Baxalta
  • Delta-Fly Pharma
  • Merck
  • PolyPid
  • Sonoran Biosciences
  • MORE
1.Preface
1.1.Scope Of The Report
1.2.Research Methodology
1.3.Chapter Outlines

2.Executive Summary

3.Introduction
3.1.The Concept Of Nanotechnology
3.2.Nanomedicine: A Potential Platform For Therapeutic Applications
3.3.Applications Of Nanomedicine
3.3.1.Drug Delivery
3.3.2.Diagnostic Techniques
3.3.3.Anti-Microbial Techniques
3.3.4.Therapeutic Techniques
3.3.5.Surgery
3.3.6.Gene Therapy
3.3.7.Imaging
3.4.Nanocarriers: Important Tools For Nanomedicine
3.4.1.Nanoparticles
3.4.2.Carbon Nanotubes (Cnts)
3.4.3.Polymer Conjugates
3.4.4.Nanocrystals
3.4.5.Dendrimers
3.5.Nanocarriers And Drug Approvals

4.Market Landscape
4.1.Chapter Overview
4.2.Dendrimers: Product List And Classes
4.3.Polymer Drug Conjugates: Development Pipeline
4.3.1.Distribution By Phase Of Development
4.3.2.Distribution By Type Of Disease Area
4.3.3.Distribution By Type Of Polymer
4.3.4.Distribution By Type Of Drug
4.3.5.Leading Players Of The Industry

5.Dendrimers: A Detailed Review
5.1.An Introduction To Dendrimers
5.2.Synthesis Of Dendrimers
5.2.1.Divergent Mode Of Synthesis
5.2.2.Convergent Mode Of Synthesis
5.3.Characterization Of Dendrimers
5.3.1.Spectroscopic Techniques
5.3.2.Microscopy
5.3.3.Size Exclusion Chromatography
5.3.4.Other Techniques
5.4.Properties Of Dendrimers
5.5.Advantages Of Dendrimers
5.6.Applications Of Dendrimers
5.6.1.Drug Delivery
5.6.2.Mimics Of Globular Proteins
5.6.3.Gene Transfection
5.6.4.Imaging And Diagnostics
5.6.5.Solubility Enhancers
5.6.6.Modification Of Electrodes
5.6.7.Development Of Vaccines
5.7.Classification Of Dendrimers
5.8.Types Of Dendrimers
5.9.Commercialized Dendrimers
5.9.1.Pamam/Starburst®
5.9.1.1.Specifications
5.9.1.2.Structure And Synthesis
5.9.1.3.Properties
5.9.1.4.Products Based On Pamam
5.9.1.5.Pamam: Application In Biopharmaceuticals
5.9.2.Poly-L-Lysine (Pll) Dendrimers (Multiple Antigen Peptide Dendrimers)
5.9.2.1.Specifications
5.9.2.2.Structure
5.9.2.3.Products Based On Pll Dendrimers
5.9.3.Priostar® Dendrimers (Frechet Type Dendrimers)
5.9.3.1.Specifications
5.9.3.2.Priostar®: Applications
5.9.3.3.Products Based On Priostar® Dendrimers
5.9.4.Astramol® (Polypropylenimine (Ppi) Dendrimer)
5.9.4.1.Specifications

6.Polymer Drug Conjugates: Drug Profiles
6.1.The Rationale Of Polymer Drug Conjugates
6.2.Designing And Characterization Of Polymer Drug Conjugates
6.3.Most Common Polymers
6.4.Most Common Drugs
6.5.Advantages Of Polymer Drug Conjugates
6.6.Polymer Drug Conjugates In Oncology And Other Diseases
6.7.Polymer Drug Conjugates: Drug Profiles
6.7.1.Nektar Therapeutics
6.7.1.1.Company Overview
6.7.1.2.Product Profile: Nktr-102 / Etirinotecanpegol
6.7.1.3.Product Profile: Nktr-181
6.7.2.Cti Biopharma
6.7.2.1.Company Overview
6.7.2.2.Product Profile: Opaxio™
6.7.3.Cerulean Pharma
6.7.3.1.Company Overview
6.7.3.2.Product Profile: Crlx101

7.Market Forecast And Opportunity Analysis
7.1.Chapter Overview
7.2.Polymer Drug Conjugates: Future Projections
7.2.1.Scope And Limitations
7.2.2.Forecast Methodology
7.2.3.Polymer Drug Conjugates Market, Late Clinical Molecules (Usd Million): 2016-2026 (Base Scenario)
7.2.3.1.Nktr-118 (Nektar Therapeutics)
7.2.3.2.Nktr-102 (Nektar Therapeutics)
7.2.3.3.Crlx101 (Cerulean Pharma)
7.2.3.4.Opaxio™ (Cti Biopharma)
7.3.Dendrimers: Opportunity Areas
7.3.1.Drug Delivery Systems
7.3.2.Research Applications
7.3.3.Therapeutic Applications
7.3.4.Diagnostic Applications

8.Conclusion
8.1.The Evolving Era Of Polymer Therapeutics Offers Significant Promise To The Pharmaceuticals Market
8.2.Amongst All The Applications, Drug Delivery Holds A Large Opportunity
8.3.The Dendrimer Market Is Yet To Unveil Itspotential In The Biomedical Industry
8.4.Polymer Drug Conjugates Are Being Exploited For Numerous Therapeutic Areas
8.5.With Success Of The Already Commercialized Drugs, The Next Generation Of Polymer Drug Conjugates Are Poised To Witness An Accelerated Growth

9.Appendix 1: Tabulated Data

10.Appendix 2: List Of Companies And Organizations

List Of Figures

Figure 3.1 Application of Nanomedicines
Figure 3.2 Nanomedicine Drug Delivery: Applications in Key Therapeutic Areas
Figure 3.3 Challenges Associated with Drug Delivery in Nanotechnology
Figure 3.4 Classification of Nanocarriers
Figure 3.5 Properties of Carbon Nanotubes
Figure 3.6 Properties of Dendrimers
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Disease Area
Figure 4.3 Pipeline Analysis: Distribution by Type of Polymer
Figure 4.4 Pipeline Analysis: Distribution by Type of Drug
Figure 4.5 Polymer Drug Conjugates: Key Players
Figure 5.1 Dendrimers: Advantages
Figure 5.2 Dendrimer versus Linear Polymers
Figure 5.3 Dendrimers: Classification
Figure 5.4 Dendrimers: Types
Figure 5.5 SuperFect® Transfection Reagent: Applications
Figure 5.6 SuperFect® Transfection Reagent: Protocol
Figure 5.7 Polyfect® Transfection Reagent: Protocol
Figure 5.8 PrioFect™: Clinical and Non-Clinical Applications
Figure 5.9 NanoJuice®Transfection Kit: Advantages
Figure 6.1 Polymer Drug Conjugates: Ringsdorf Model
Figure 6.2 Polymer Drug Conjugates: Advantages
Figure 6.3 Application of Polymer Drug Conjugates in Several Indications
Figure 6.4 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Figure 6.5 PEGylatedIrinotecan: NKTR-102
Figure 6.6 NKTR-102: Mechanism of Action
Figure 6.7 Advantages of NKTR-102 over Irinotecan
Figure 7.1 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Figure 7.2 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Figure 7.3 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.4 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.5 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.6 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.7 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.8 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.9 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.10 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.11 Collaboration Based Revenues: Illustrative Future Projections
Figure 8.1 Polymer Therapeutics versus Conventional Therapeutic
Figure 8.2 Polymer Drug Conjugates: Emerging Therapeutic Areas
Figure 8.3 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026

List Of Tables

Table 3.1 Approved Nanocrystal Drugs
Table 3.2 List of Commercialized Nanomedicines
Table 4.1 Dendrimers: Product List and Classes
Table 4.2 Polymer Drug Conjugates: Development Pipeline
Table 5.1 List of Drugs Loaded in Dendrimers
Table 5.2 List of Commercialized Dendrimers
Table 5.3 Dendritech: List of PAMAM Dendrimers
Table 5.4 Stratus® CS: Type of Biomarkers
Table 5.5 SuperFect™ Transfection Reagent: Product Details
Table 5.6 PolyFect™ Transfection Reagent: Product Details
Table 5.7 PolyFect™ Transfection Reagent: Product Details
Table 5.8 PAMAM: Biotherapeutic Applications
Table 5.9 VivaGel®: Current Status of Development
Table 5.10 VivaGel®: Current Status of Development
Table 5.11 VivaGel®: Clinical Trial Endpoints
Table 5.12 Gadomer-17: Product Specifications
Table 5.13 PPI Dendrimers: Price and Quantity
Table 6.1 Approved Polymer Drug Conjugates
Table 6.2 Polymer Drug Conjugates: Profiled Drugs
Table 6.3 NKTR-102: Current Status of Development
Table 6.4 NKTR-102: Clinical Trials
Table 6.5 NKTR-102: Phase II Clinical Trial Endpoints (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer)
Table 6.6 NKTR-102: Phase II Clinical Trial Endpoints (Glioma, Solid Tumors)
Table 6.7 NKTR-102 versus TPC: Adverse Events
Table 6.8 NKTR-181: Current Status of Development
Table 6.9 NKTR-181: Clinical Trials
Table 6.10 NKTR-181: Clinical Trials
Table 6.11 Opaxio™: Current Status of Development
Table 6.12 Opaxio™: Clinical Studies
Table 6.13 Opaxio™: Clinical Trial Endpoints for Ovarian Epithelial, Peritoneal and Fallopian Tube Cancer
Table 6.14 Opaxio™: Clinical Trial Endpoints for Other Indications
Table 6.15 CRLX101: Current Status of Development
Table 6.16 CRLX101: Clinical Studies
Table 6.17 CRLX101: Clinical Trial Endpoints (Phase II Studies)
Table 6.18 CRLX101: Clinical Trial Endpoints (Phase I/II Studies)
Table 7.1 Polymer Drug Conjugates: Market Potential of Candidates
Table 7.2 NKTR-181: Target Patient Population
Table 7.3 NKTR-102: Target Patient Population
Table 7.4 CRLX101: Target Patient Population
Table 7.5 Opaxio™: Target Patient Population
Table 7.6 Dendrimers: Opportunity Areas
Table 7.7 Drug Delivery Systems: Example List
Table 7.8 Commercialized Dendrimer-Based Kits
Table 9.1 Pipeline Analysis: Distribution by Phase of Development
Table 9.2 Pipeline Analysis: Distribution by Type of Disease Area
Table 9.3 Pipeline Analysis: Distribution by Type of Polymer
Table 9.4 Pipeline Analysis: Distribution by Type of Drug
Table 9.5 Polymer Drug Conjugates: Key Players
Table 9.6 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Table 9.7 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Table 9.8 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Optimistic Scenario)
Table 9.9 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Conservative Scenario)
Table 9.10 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Table 9.11 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.12 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.13 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.14 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.15 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.16 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.17 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.18 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.19 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.20 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.21 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.22 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.23 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.24 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.25 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.26 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.27 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.28 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.29 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.30 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.31 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.32 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.33 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.34 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.35 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- 3S Bio
- ASCEND Therapeutics
- Abeona Therapeutics
- Abramson Cancer Center
- Access Pharmaceuticals
- Adama
- Ajinomoto Althea
- Allergan
- Alliance for Clinical Trials in Oncology
- Allied Corporation
- Althea Technologies
- Altus Pharmaceuticals
- Amgen
- Ansell Limited
- Arsenal Medical
- Ascendis Pharma
- Aspen Pharmacare
- AstraZeneca
- BIND Sciences
- Baxalta
- Belrose Pharma
- Beth Israel Deaconess Medical Center
- Biogen
- Brown University
- CTI BioPharma
- Cancer Therapeutics
- Carlina Technologies
- Cellular Therapeutics
- Cerulean Pharma
- City of Hope Medical Center
- Clemson University
- Colcom
- Cosmo Pharmaceuticals
- Crealta Pharmaceuticals
- CytImmune
- Dade Behring
- Dana-Farber Cancer Institute
- Dartmouth-Hitchcock Medical Center
- DelSiTech
- Delta-Fly Pharma
- Dendritech Nanotechnologies
- Dow Chemical
- Durect Corporation
- EMD Biosciences
- Edge Therapeutics
- Eli Lilly
- Enzon Pharmaceuticals
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Eyetech
- Ferring
- Flamel Technologies
- Genentech
- GlaxoSmithKline
- Gowan
- Gynecologic Oncology Group Foundation
- JenKem Technology
- Landec
- Lipotek
- M.D. Anderson Cancer Center
- MakhteshimAgan
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Memorial Sloan Kettering Cancer Center
- Merck
- Mersana Therapeutics
- Michigan Nanotechnology Institute for Medicine and Biological Sciences
- Mountain View Pharmaceuticals
- Mylan
- Nanovector
- National Cancer Institute
- National Heart and Lung Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Mental Health
- National Institute on Drug Abuse
- National Institutes of Health
- National Nanotechnology Initiative
- Nektar Therapeutics
- NeuroNano Pharma
- Novartis
- Nufarm
- Oakwood Laboratories
- Octoplus
- Okamoto Industries
- Ontario Institute for Cancer Research
- PG-TXL
- Peptineo
- Pfizer
- Pharmacia and Upjohn Company
- PolyActiva
- PolyPid
- Polymer Factory
- ProCore Bio Med
- ProLynx
- Qiagen
- Reckitt Benckiser
- Rexahn Pharmaceuticals
- Roche
- Roswell Park Cancer Institute
- SUNY Upstate Medical University
- Sagent Pharmaceuticals
- Sanofi-Aventis
- Santarus
- Savient Pharmaceuticals
- Schering Plough
- Serina Therapeutics
- Shire
- Sigma Aldrich
- Sitka Biopharma
- Sloan-Kettering Institute for Cancer Research
- Sonoran Biosciences
- Stanford Cancer Institute
- Stanford University
- Starpharma
- Stiefel Laboratories
- Sun Pharma
- SyMO-Chem
- Teva Pharmaceutical
- The Methodist Hospital System
- The State University of New York
- UCB Pharma
- UNC Lineberger Comprehensive Cancer Center
- US Army Research Laboratory
- University of Chicago
- University of Colorado Boulder
- University of Glasgow
- University of Illinois
- University of Maryland
- University of Pennsylvania
- University of Southern California
- University of Washington
- Weihai CY
- World Health Organization
- Wyss Institute
- XstalBio
- Yamanouchi Pharmaceutical
- pSivida
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll